The Role of Galectin-3 in Acute Myocardial Infarction: A Narrative Literature Review
DOI:
https://doi.org/10.37275/bsm.v6i16.709Keywords:
Acute myocardial infarction, Atherosclerosis, Fibroblast, Galectin-3, Low-density lipoproteinAbstract
Galectin-3 (Gal-3) is a protein, namely a lectin, that binds to beta galactosides. Gal-3 has been shown to be related to the process of fibrosis, classification of atherosclerosis, and cardiac remodeling. Gal-3 regulation is known to be involved in the process of atherogenesis. Low-density lipoprotein (LDL) Oxidation increases Gal-3 expression in vascular smooth muscle cells. Gal-3 also induces fibroblasts and vascular smooth muscle cells to proliferate and produce fibrosis-related proteins in the extracellular matrix. Inhibition of Gal-3 can reduce the atherosclerotic process and reduce the progression of plaque formation. Gal-3 also induces fibroblasts and vascular smooth muscle cells to proliferate and produce fibrosis-related proteins in the extracellular matrix. Inhibition of Gal-3 can reduce the atherosclerotic process and reduce the progression of plaque formation. Several clinical trials have focused on the role of Gal-3 in acute myocardial infarction patients showing that Gal-3 is upregulated. In these patients. This literature review aims to describe the role of Gal-3 in acute myocardial infarction.
Authors
- Haviz Reddy1*
- Akmal M. Hanif2
- Taufik Rizkian2
- Wahyudi2
- 1Department of Internal Medicine, Faculty of Medicine, Universitas Andalas, Padang, Indonesia
- 2Cardiovascular Division, Department of Internal Medicine, Faculty of Medicine, Universitas Andalas/Dr. M. Djamil General Hospital, Padang, Indonesia
Corresponding author Haviz Reddy — havizreddy@gmail.com
Article history
- Submitted
- Accepted
- Published
Downloads
Published
Issue
Section
License
Copyright and licensing
Copyright in each article remains with the author(s). Authors grant Bioscientia Medicina: Journal of Biomedicine and Translational Research a non-exclusive right of first publication and the right to identify itself as the original publisher. No exclusive transfer of copyright is required.
All articles are published under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0): https://creativecommons.org/licenses/by-nc-sa/4.0/. Users may copy, redistribute, remix, transform, and build upon the material for non-commercial purposes, provided appropriate attribution is given, a link to the license is supplied, changes are indicated, and adaptations are distributed under the same license.
The license applies to the article's scholarly content unless a credit line states otherwise. Third-party material may be subject to separate rights. Authors retain patent, trademark, moral, and research-data rights. The copyright year follows the article's publication date.
